MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.260 +0.080 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Six ASCO abstracts and an industry expert theater session underscore Myriad’s leadership in the cancer care continuum 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
The Netflix star partners with Myriad Genetics to tell her BRCA1 story and why she wants everyone to know about hereditary cancer testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Launch Represents Significant Step to Broader Commercialization 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Management will participate in three upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
Actionable offering helps enable earlier, more personalized breast cancer interventions 
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story